Advanced Renal Cell Carcinoma
Advertisement
PFS was improved with nivolumab plus cabozantinib.
A lack of research persists on the duration of therapy as well as the safety and efficacy of reinduction at progression.
The hypoxia-inducible factor 2α inhibitor, belzutifan, has shown clinical activity in patients with ccRCC.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
Dr. Braun shares insights on updates to the NCCN guidelines for RCC, highlighting how they could impact clinical practice.
Patients who received nivolumab plus ipilimumab experienced increased complete response rates compared with sunitinib.
Researchers stated that the novel data source has the potential to inform patient care.
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
Bempegaldesleukin can initialize effector CD8+ T cells and natural killer cells in the tumor microenvironment.
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
The discussion focused on advanced and metastatic stages of RCC, shedding light on current practices in clinics.
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
The KEYNOTE-426 study explored pembrolizumab and axitinib vs sunitinib in advanced RCC using genetic biomarkers.
Drs. Semaan and El Zarif detail an investigation into first-line systemic therapy following adjuvant immunotherapy for RCC.
Dr. Grünwald showcases patterns of progression and subsequent therapy for patients receiving len/pembro for aRCC.
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
Patients who received lenvatinib plus pembrolizumab experienced later progression across tumors in multiple organs.
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Investigators found that the median follow-up period was 16.5 months at the study’s cutoff date.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.